Form 4: OptimizeRx Director Cathy Klema Receives Equity Grant as Part of Compensation

OptimizeRx Corporation's Director, Cathy Klema, was granted 9,868 restricted stock units (RSUs) on June 11, 2025, as part of her compensation, aligning her interests with shareholders.

Summary

• Cathy Klema, a Director of OptimizeRx Corp (OPRX), acquired 9,868 shares of common stock on June 11, 2025.
• The acquisition was a grant of restricted stock units (RSUs) with a transaction price of $0 per share.
• Following this transaction, Cathy Klema beneficially owns a total of 21,620 shares of OptimizeRx common stock.
• The restricted stock units are contingent rights to receive shares and will vest in full on the earlier of the first anniversary of the grant date or the date of the Company's next annual meeting of shareholders.

Sentiment

Score: 7

Explanation: The sentiment is positive as the RSU grant aligns the director's interests with shareholders, which is a standard and beneficial corporate governance practice. It does not indicate any negative operational or financial news.

Positives

• The grant of restricted stock units to a director aligns management and board interests with those of the shareholders, as the value of the compensation is tied to the company's stock performance.
• Equity-based compensation is a common and effective way to incentivize long-term commitment and performance from board members.

Future Outlook

The granted restricted stock units are subject to a future vesting schedule, which will occur on the earlier of the first anniversary of the grant date (June 11, 2026) or the date of the Company's next annual meeting of shareholders, indicating a future increase in the director's direct share ownership upon vesting.

Industry Context

The grant of restricted stock units to a director is a standard practice in corporate governance across various industries, particularly in the technology and healthcare sectors where OptimizeRx operates. It is a common method for compensating non-employee directors and aligning their long-term interests with the company's performance and shareholder value creation.

Comparison to Industry Standards

• The use of restricted stock units (RSUs) for director compensation is a widely adopted practice among publicly traded companies, including those comparable to OptimizeRx in the digital health and pharmaceutical technology sectors.
• Companies like Veeva Systems (VEEV) and Doximity (DOCS) also frequently utilize equity grants, such as RSUs or stock options, as a significant component of their non-employee director compensation packages to foster long-term alignment and retention.
• The vesting schedule, tied to either a one-year anniversary or the next annual meeting, is typical for such grants, ensuring continued engagement and oversight from the board member.

Corporate Governance

Related Party Transactions

• The grant of restricted stock units to Cathy Klema, a director of OptimizeRx, constitutes a related party transaction as it involves compensation from the company to a member of its board of directors. This is a standard and disclosed form of compensation.

Stakeholder Impact

• Shareholders: The grant aligns the director's interests with shareholders, potentially leading to decisions that enhance long-term shareholder value.
• Employees: No direct impact on employees is indicated by this specific filing, though equity compensation is a common practice across various levels of a company.

Next Steps

• The restricted stock units will vest on the earlier of June 11, 2026, or the date of OptimizeRx's next annual meeting of shareholders, at which point the shares will be issued to Cathy Klema.

Key Dates

Keywords

OptimizeRx, OPRX, Form 4, Insider Transaction, Restricted Stock Units, RSU Grant, Director Compensation, Equity Compensation, Beneficial Ownership